Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 8/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1194072 | 1.00 | TLR9 (0.53) | TLR9EGFRPTGES2MEN1ALDH1A1 | |
| SCHEMBL5572469 | 0.86 | TLR9 (0.64) | TLR9EGFRALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL29149692 | 0.86 | TLR9 (0.64) | TLR9EGFRALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL5572462 | 0.86 | TLR9 (0.64) | TLR9EGFRALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL1195448 | 0.82 | NFE2L2 (0.53) | NFE2L2 | |
| SCHEMBL28880759 | 0.82 | TLR9 (0.60) | TLR9EGFRPTGES2MEN1ALDH1A1 | |
| SCHEMBL1195446 | 0.82 | NFE2L2 (0.53) | NFE2L2 | |
| SCHEMBL1195313 | 0.81 | NFE2L2 (0.57) | TLR9EGFRPTGES2NFE2L2PPARG | |
| SCHEMBL30987467 | 0.81 | TLR9 (0.59) | TLR9EGFRPTGES2MEN1ALDH1A1 | |
| SCHEMBL1195311 | 0.81 | NFE2L2 (0.57) | TLR9EGFRPTGES2NFE2L2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027330-B1 | STYRYL SULFONE ANTICANCER AGENTS | UNIV TEMPLE (US) | 2004-12-08 | — | — | EP | claimed |
| EP-1027330-A4 | STYRYL SULFONE ANTICANCER AGENTS | UNIV TEMPLE (US) | 2003-09-10 | — | — | EP | claimed |
| US-20030114538-A1 | Styryl sulfone anticancer agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2003-06-19 | — | — | US | claimed |
| US-6548553-B2 | Therapy of proliferative disease other than prostate or breast cancer comprising administering styryl sulfone derivative | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2003-04-15 | — | — | US | claimed |
| US-6359013-B1 | BREAST AND PROSTATE CANCER; AFFECT THE MAPK SIGNAL TRANSDUCTION PATHWAY, THEREBY TUMOR CELL GROWTH; INHIBIT THE GROWTH OF TUMOR CELLS WITHOUT AFFECTING NORMAL CELLS; 4-FLUOROSTYRYL 4-BROMOBENZYL SULFONE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-03-19 | — | — | US | claimed |
| US-20020022666-A1 | Styryl sulfone anticancer agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-02-21 | — | — | US | claimed |
| WO-2000059494-A1 | STYRYL SULFONE ANTICANCER AGENTS | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2000-10-12 | — | — | WO | claimed |
| EP-1027330-A1 | STYRYL SULFONE ANTICANCER AGENTS | Temple University of the Commonwealth System of Higher Education (US) | 2000-08-16 | — | — | EP | claimed |
| WO-1999018068-A1 | STYRYL SULFONE ANTICANCER AGENTS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1999-04-15 | — | — | WO | claimed |
| US-20150238448-A1 | FORMULATION OF RADIOPROTECTIVE ALPHA, BETA UNSATURATED ARYL SULFONES | ONCONOVA THERAPEUTICS, INC (US) | 2015-08-27 | — | — | US | disclosed |
| EP-2769719-A1 | Formulations of radioprotective alpha, beta unsaturated aryl sulfones | Onconova Therapeutics, Inc. (US) | 2014-08-27 | — | — | EP | disclosed |
| EP-2046343-B1 | FORMULATIONS OF RADIOPROTECTIVE ALPHA, BETA UNSATURATED ARYL SULFONES | ONCONOVA THERAPEUTICS INC (US) | 2014-05-14 | — | — | EP | disclosed |
| EP-1909775-B1 | FORMULATION OF RADIOPROTECTIVE ALPHA, BETA UNSATURATED ARYL SULFONES | ONCONOVA THERAPEUTICS INC (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20110028504-A1 | Formulation of radioprotective alpha beta unsaturated aryl sulfones | ONCONOVA THERAPEUTICS, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-6359013-B1 | BREAST AND PROSTATE CANCER; AFFECT THE MAPK SIGNAL TRANSDUCTION PATHWAY, THEREBY TUMOR CELL GROWTH; INHIBIT THE GROWTH OF TUMOR CELLS WITHOUT AFFECTING NORMAL CELLS; 4-FLUOROSTYRYL 4-BROMOBENZYL SULFONE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-03-19 | — | — | US | disclosed |
| US-20020022666-A1 | Styryl sulfone anticancer agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-02-21 | — | — | US | disclosed |
| WO-2001026645-A1 | METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2001-04-19 | — | — | WO | disclosed |
| WO-2000059494-A1 | STYRYL SULFONE ANTICANCER AGENTS | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2000-10-12 | — | — | WO | disclosed |
| EP-1027330-A1 | STYRYL SULFONE ANTICANCER AGENTS | Temple University of the Commonwealth System of Higher Education (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999018068-A1 | STYRYL SULFONE ANTICANCER AGENTS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114538-A1 | Styryl sulfone anticancer agents | BCL2, MCL1, BCL2A1 | TLR9 1895/4885EGFR 264/4885PTGES2 4127/4885 |
| US-20020022666-A1 | Styryl sulfone anticancer agents | BCL2, MCL1, BCL2A1 | TLR9 1895/4885EGFR 264/4885PTGES2 4127/4885 |
| US-20150238448-A1 | FORMULATION OF RADIOPROTECTIVE ALPHA, BETA UNSATURATED ARYL SULFONES | ARSA, AHR, SULT2A1 | TLR9 2457/4885EGFR 2617/4885PTGES2 465/4885 |
| US-20110028504-A1 | Formulation of radioprotective alpha beta unsaturated aryl sulfones | DEGS1, ARSA, ABCE1 | TLR9 2102/4885EGFR 1965/4885PTGES2 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.